Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

NM. Czuczman, MJ. Barth, J. Gu, V. Neppalli, C. Mavis, SE. Frys, Q. Hu, S. Liu, P. Klener, P. Vockova, MS. Czuczman, FJ. Hernandez-Ilizaliturri,

. 2016 ; 127 (9) : 1128-1137. [pub] 20151216

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16027835

Grant support
NT13072 MZ0 CEP Register
NT13201 MZ0 CEP Register

Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel potent and selective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary MCL tumor cells, and 2 distinct murine models of human MCL. Pevonedistat exposure resulted in a dose-, time-, and caspase-dependent cell death in the majority of the MCL cell lines and primary tumor cells tested. Of interest, in the MCL cell lines with lower half-maximal inhibitory concentration (0.1-0.5 μM), pevonedistat induced G1-phase cell cycle arrest, downregulation of Bcl-xL levels, decreased nuclear factor (NF)-κB activity, and apoptosis. In addition, pevonedistat exhibited additive/synergistic effects when combined with cytarabine, bendamustine, or rituximab. In vivo, as a single agent, pevonedistat prolonged the survival of 2 MCL-bearing mouse models when compared with controls. Pevonedistat in combination with rituximab led to improved survival compared with rituximab or pevonedistat monotherapy. Our data suggest that pevonedistat has significant activity in MCL preclinical models, possibly related to effects on NF-κB activity, Bcl-xL downregulation, and G1 cell cycle arrest. Our findings support further investigation of pevonedistat with or without rituximab in the treatment of MCL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027835
003      
CZ-PrNML
005      
20191015140252.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2015-04-640920 $2 doi
024    7_
$a 10.1182/blood-2015-04-640920 $2 doi
035    __
$a (PubMed)26675347
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Czuczman, Natalie M $u Department of Pediatrics, Departments of Medicine and Immunology.
245    10
$a Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo / $c NM. Czuczman, MJ. Barth, J. Gu, V. Neppalli, C. Mavis, SE. Frys, Q. Hu, S. Liu, P. Klener, P. Vockova, MS. Czuczman, FJ. Hernandez-Ilizaliturri,
520    9_
$a Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel potent and selective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary MCL tumor cells, and 2 distinct murine models of human MCL. Pevonedistat exposure resulted in a dose-, time-, and caspase-dependent cell death in the majority of the MCL cell lines and primary tumor cells tested. Of interest, in the MCL cell lines with lower half-maximal inhibitory concentration (0.1-0.5 μM), pevonedistat induced G1-phase cell cycle arrest, downregulation of Bcl-xL levels, decreased nuclear factor (NF)-κB activity, and apoptosis. In addition, pevonedistat exhibited additive/synergistic effects when combined with cytarabine, bendamustine, or rituximab. In vivo, as a single agent, pevonedistat prolonged the survival of 2 MCL-bearing mouse models when compared with controls. Pevonedistat in combination with rituximab led to improved survival compared with rituximab or pevonedistat monotherapy. Our data suggest that pevonedistat has significant activity in MCL preclinical models, possibly related to effects on NF-κB activity, Bcl-xL downregulation, and G1 cell cycle arrest. Our findings support further investigation of pevonedistat with or without rituximab in the treatment of MCL.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a kaspasy $x metabolismus $7 D020169
650    _2
$a kontrolní body buněčného cyklu $x účinky léků $7 D059447
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a separace buněk $7 D002469
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cyklopentany $x farmakologie $x terapeutické užití $7 D003517
650    _2
$a inhibitory enzymů $x farmakologie $x terapeutické užití $7 D004791
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x genetika $x patologie $7 D020522
650    _2
$a myši SCID $7 D016513
650    _2
$a NF-kappa B $x metabolismus $7 D016328
650    _2
$a protoonkogenní proteiny c-bcl-2 $x metabolismus $7 D019253
650    _2
$a pyrimidiny $x farmakologie $x terapeutické užití $7 D011743
650    _2
$a rituximab $x farmakologie $x terapeutické užití $7 D000069283
650    _2
$a knihovny malých molekul $x farmakologie $x terapeutické užití $7 D054852
650    _2
$a ubikvitiny $x antagonisté a inhibitory $x metabolismus $7 D014452
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Barth, Matthew J $u Department of Pediatrics, Departments of Medicine and Immunology.
700    1_
$a Gu, Juan $u Departments of Medicine and Immunology.
700    1_
$a Neppalli, Vishala $u Department of Pathology, and.
700    1_
$a Mavis, Cory $u Departments of Medicine and Immunology.
700    1_
$a Frys, Sarah E $u Department of Pediatrics, Departments of Medicine and Immunology.
700    1_
$a Hu, Qiang $u Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY;
700    1_
$a Liu, Song $u Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY;
700    1_
$a Klener, Pavel, $u Department of Pediatrics, University of Buffalo, Buffalo, NY; and Clinical Department of Hematology, Institute of Pathophysiology, Charles University in Prague, Prague, Czech Republic. $d 1975- $7 xx0105452
700    1_
$a Vockova, Petra $u Department of Pediatrics, University of Buffalo, Buffalo, NY; and Clinical Department of Hematology, Institute of Pathophysiology, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Czuczman, Myron S $u Departments of Medicine and Immunology.
700    1_
$a Hernandez-Ilizaliturri, Francisco J $u Departments of Medicine and Immunology.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 127, č. 9 (2016), s. 1128-1137
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26675347 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20191015140718 $b ABA008
999    __
$a ok $b bmc $g 1166149 $s 952465
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 127 $c 9 $d 1128-1137 $e 20151216 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a NT13072 $p MZ0
GRA    __
$a NT13201 $p MZ0
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options